Cytori Receives $12 Million for the First Installment from the Lorem Vascular Partnership Equity Agreement

  Cytori Receives $12 Million for the First Installment from the Lorem
  Vascular Partnership Equity Agreement

Business Wire

SAN DIEGO -- November 7, 2013

Cytori Therapeutics (NASDAQ: CYTX) has received the first $12 million
installment from the equity agreement with newly formed Lorem Vascular. The
equity agreement is part of Cytori’s partnership announced earlier this week
with Lorem Vascular to commercialize Cytori Cell Therapy for the
cardiovascular, renal and diabetes markets in China, Hong Kong, Malaysia,
Singapore and Australia. Under the terms of the equity agreement, Cytori will
receive $24 million in exchange for 8 million shares of Cytori common stock at
$3.00 per share in two installments. The second $12 million payment will be
made before the end of the year.

Cytori’s management will discuss the Lorem Vascular partnership today,
November 7, as part of its quarterly results and business update at 5:00 PM
Eastern Time. The dial-in information is as follows:

Dial-In Number: +1.877.402.3914
Conference ID: 95080960

The webcast will be available both live and by replay two hours after the call
in the “Webcasts” section of the Company's Investor Relations website.

About Cytori

Cytori Therapeutics is developing cell therapies based on autologous
adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and
other medical conditions. Our scientific data suggest ADRCs improve blood
flow, moderate the inflammatory response and keep tissue at risk of dying
alive. As a result, we believe these cells can be applied across multiple
“ischemic” conditions. These therapies are made available to the physician and
patient at the point-of-care by Cytori’s proprietary technologies and
products, including the Celution System product family. www.cytori.com

Contact:

Cytori Therapeutics
Tom Baker, +1.858.458.0900
 
Press spacebar to pause and continue. Press esc to stop.